Net specialty spend reached $1,251 PMPY in 2025, driven primarily by rising utilization and member penetration, rather than ...

A randomized, open-label comparison in 31 children (mostly cerebral palsy) evaluated VR plus nitrous oxide versus standard distraction approaches during botulinum toxin injections. Pain scores ...

Retinal anti-VEGF regimens requiring frequent monitoring generate indirect patient costs that often outweigh direct expenses ...

Management tools are intensifying across markets, including more prior authorization, step therapy, formulary exclusions, and biosimilar preferencing, with spillover from Part D into commercial ...

Require each hospital and care provider to post a single commercial (private insurance) price for each care location, expressed as a simple multiple of the price Medicare pays.

For individuals living with chronic conditions, stable housing enables consistent care. Conversely, housing instability can disrupt care continuity, increase financial strain, and contribute to ...

Edward Machtinger, M.D., of UCSF says most mental illness and substance use trace back to trauma, and clinics that ignore this can retraumatize patients.

CMS will terminate the Part D premium stabilization subsidies for standalone PDPs in 2027, citing mature sponsor pricing under IRA benefit redesign and a return to “traditional market conditions.” ...

Questions about price and access hover over the positive results for a weekly HIV treatment pill that combines Merck’s islatravir and Gilead’s lenacapavir. Prospects for a weekly pill for HIV ...

Zambia's Lloyd Mulenga, M.B.Ch.B., Ph.D., says U.S. funding cuts pushed African governments toward domestic financing, but he fears for HIV prevention.

Simtriyo’s mechanism combines norepinephrine/dopamine augmentation with serotonin modulation, expanding beyond traditional stimulant and selective nonstimulant approaches for heterogeneous ADHD ...